An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Children with Attention-Deficit/Hyperactivity Disorder (ADHD) are typically treated with two
types of medications with differing mechanisms of action: stimulants and non-stimulants. The
stimulant Vyvanse (lisdexamfetamine, LDX), and the non-stimulant Intuniv (extended-release
guanfacine, GXR), are both FDA approved treatment for ADHD. Clinical trials have shown that
both medications are effective in reducing ADHD symptoms, although the neurobiological
mechanisms by which Vyvanse and Intuniv produce these effects remain unknown. The aim of this
study is to examine the mechanisms by which LDX and GXR reduce symptoms in patients with
ADHD. MRI scanning will be used to identify treatment-related changes in brain structure and
function.
Phase:
N/A
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
American Academy of Child Adolescent Psychiatry. Columbia University Shire